Cannabidiol and pharmacokinetics drug-drug interactions: Pharmacological toolbox

Clémence Lacroix; Romain Guilhaumou; Joëlle Micallef; Olivier Blin

doi:10.1016/j.therap.2023.05.003

Cannabidiol and pharmacokinetics drug-drug interactions: Pharmacological toolbox

Therapie. 2023 May 29:S0040-5957(23)00080-X. doi: 10.1016/j.therap.2023.05.003. Online ahead of print.

Authors

Clémence Lacroix¹, Romain Guilhaumou², Joëlle Micallef², Olivier Blin²

Affiliations

¹ Aix Marseille Univ, APHM, INSERM, Inst Neurosci Syst, UMR 1106, University Hospital Federation DHUNE, Service de Pharmacologie Clinique et Pharmacovigilance, 13005 Marseille, France. Electronic address: clemence.lacroix@ap-hm.fr.
² Aix Marseille Univ, APHM, INSERM, Inst Neurosci Syst, UMR 1106, University Hospital Federation DHUNE, Service de Pharmacologie Clinique et Pharmacovigilance, 13005 Marseille, France.

PMID: 37296021
DOI: 10.1016/j.therap.2023.05.003

Abstract

Cannabidiol (CBD) is one of the most important components of the Cannabis sativa plant with delta9-tetrahydrocannabinol (THC). CBD is used both for medical and recreational purposes. It can be of pharmaceutical grade (Epidyolex®), and also self-service purchased in pharmacy, CBD shops and on the internet (non-pharmaceutical). CBD is almost as widespread as it is poorly understood from a pharmacological point of view and particularly in terms of drug interactions. Drug-drug interactions could lead to clinical complications, and we here gather data currently available on pharmacokinetics (PK) drug-drug interactions with CBD through a narrative review. This review shows that several PK drug-drug interactions exist with different class of medications and aims to help clinicians to better know about CBD for their practice as this product is increasingly used.

Keywords: Cannabidiol; Drug-drug interactions; Pharmacokinetics; Pharmacology.